profit from every $100 of sales.
$0$100
Evogene
$0.29+6.09% today
-75.0% in 1 year
1-year low $0.271-year high $1.25
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Evogene sold, what it kept, and what it did with the cash.
Sales went from $1.68 million in 2022 to $3.85 million in 2025, with -$8.49 million of profit last year.
SalesProfit
Evogene vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Evogene | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Evogene's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2 | 3 | 6 | 4 | |
| 1 | 1 | 3 | -0 | |
| -27 | -22 | -19 | -14 | |
| -27 | -21 | -13 | -12 | |
| -27 | -24 | -16 | -8 | |
| -6.50 | -5.20 | -2.89 | -1.08 | |
| 45.7% | 50.0% | 57.3% | -6.3% | |
| -1,608.4% | -745.5% | -337.2% | -364.2% | |
| -1,590.3% | -800.8% | -295.6% | -220.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 56 | 51 | 40 | 20 |
| Cash | 29 | 21 | 15 | 13 |
| Total debt | 12 | 12 | 13 | 2 |
| Total liabilities | 21 | 22 | 25 | 8 |
| 28 | 12 | -1 | -0 | |
| 4 | 5 | 6 | 8 | |
| -58.6% | -73.2% | -102.0% | -498.1% | |
| -95.4% | -198.1% | 1,136.1% | 10,347.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -24 | -22 | -20 | -14 | |
| 1 | 1 | 1 | 0 | |
| -25 | -22 | -20 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- -87.7×
- 1.3×
- –
- –
- -262.8%
- -163.5%
- 0.0%
Profitability
- -6.3%
- -364.2%
- -220.2%
- -284.9%
- -82.6%
- -152.6%
- 553.2%
- -42.3%
- -89.8%
- 213.7%
Growth
- +32.0%
- –
- +32.9%
- –
- −33.8%
Financial health
- -0.9×
- -26.80
- 11.0%
- -7.9×
- 4.38
- 4.32
- 0.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 948
Top 18%of 868
What analysts expect
- Average price target
- $3.50
- Range
- $3.50 – $3.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 5, 2026 | -0.61 | -0.26 | −134.6% |
| Nov 20, 2025 | -0.31 | -0.26 | −19.2% |
| Aug 28, 2025 | -1.06 | – | – |
| May 21, 2025 | -0.38 | -0.63 | +39.2% |
| Mar 6, 2025 | 0.06 | -0.72 | +108.3% |
| Nov 21, 2024 | -1.31 | -1.01 | −29.7% |
| Aug 22, 2024 | -1.06 | -0.12 | −783.3% |
| May 23, 2024 | -0.80 | -0.09 | −788.9% |
News
Evogene Q2 2026 Earnings PreviewSeeking Alpha · Aug 17, 2026The newest story we have is from Aug 17, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
50No pass
Philip Fisher
47No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
40No pass
Terry Smith
44No pass
Questions about Evogene
Is Evogene a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Evogene AI analysis
What does Evogene do?
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It is in Biotechnology.
Does Evogene pay a dividend?
No. Evogene does not pay a dividend at the moment.
Is Evogene stock halal?
No. Evogene does not pass our halal screen: its debt is 42% of its market value, at or above the 33% limit. How we check
How has Evogene stock done over the past year?
Down 75.0% over the past twelve months, to $0.29. It traded between $0.27 and $1.25 and is 77.0% below its high.
Who are Evogene's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Evogene's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.